50 rue de Dijon
About InventivaInventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage whose objective is to develop and provide patients with new therapies. The focus of the company’s research and developmentdepartment targets three promising areas, namely fibrotic diseases, the treatment of certain forms of lysosomal diseases and oncology with a priority for the development of indications for orphan diseases for which the unmet medical need and the regulations in force allow an accelerated development.
Founder and CEO: Frédéric Cren
Founder and CSO: Pierre Broqua
CFO: Jean Volatier
CMO: Jean-Louis Abitbol
Please click here for Inventiva job opportunities.
Please click here for clinical trial information.
Tweets by Inventiva Pharma
38 articles with Inventiva
10/15/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
NASH is a metabolic disease similar to cirrhosis of the liver, but occurs in people who drink little, if any, alcoholic.
5/28/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
5/21/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
4/9/2020Biopharma companies from across the globe provide updates to their business operations and pipelines.
12/5/2019Companies from across the globe provide updates on their business and pipelines.
10/3/2019Companies from across the globe share information on their business and pipelines.
9/26/2019Companies from across the globe share updates on their business and pipelines.
9/12/2019Companies and organizations from across Europe, Asia and North America share updates on their business and pipelines.
9/5/2019Companies from across Europe and Asia share updates on their business and pipelines.
8/29/2019Companies from across the globe provide updates on their business and pipelines.
8/22/2019Companies from across the globe provide updates on their business and pipelines.
6/13/2019Companies from across the globe share business and pipeline updates.
Companies across Europe and Asia provide information about deal, clinical trials and more, with news from Synaptive Medical, Epic, Inventiva, Velabs, and more.
Shares of France-based Inventiva have plunged more than 45 percent after the company reported that its experimental treatment for a rare autoimmune disease failed to hit primary and secondary endpoints in a mid-stage trial.
Inventiva today announced that Frédéric Cren, CEO of Inventiva, will present at two upcoming investor conferences.
Revenues of €6.0 million, an increase of 4.6% compared to 2016
Inventiva announced that it has completed the enrollment of its Phase IIb FASST (For A Systemic Sclerosis Treatment) trial in Systemic Sclerosis (SSc) with lanifibranor, formerly known as IVA337.